Correspondence  |   August 2010
Statins Might Contribute to Postoperative Delirium
Author Affiliations & Notes
  • John C. Drummond, M.D., F.R.C.P.C.
  • *Veterans Administration Medical Center San Diego, San Diego, California.
Article Information
Correspondence   |   August 2010
Statins Might Contribute to Postoperative Delirium
Anesthesiology 8 2010, Vol.113, 500-501. doi:10.1097/ALN.0b013e3181e33bf7
Anesthesiology 8 2010, Vol.113, 500-501. doi:10.1097/ALN.0b013e3181e33bf7
To the Editor:
In the timely and welcome discussion by Mantz et al.  1 of postoperative delirium in an octogenarian, the patient's preoperative use of a statin is mentioned but is not considered in the discussion of the etiology of the delirium. The possibility that the statin might have contributed was set aside on the basis of a single retrospective investigation in which investigators at the University of Toronto, Toronto, Ontario, Canada, observed a lesser incidence of delirium after cardiac surgery, performed with cardiopulmonary bypass, among preprocedure statin takers.2 However, we hope that both clinicians and clinical investigators will maintain in mind the possibility that statins might, in at least some circumstances, contribute to postoperative delirium or cognitive dysfunction. We grant quickly that the supporting information is limited. However, in a retrospective review of a large Canadian database, other investigators at the University of Toronto reported an increase in the incidence of delirium after noncardiac surgery among patients older than 65 yr who had been receiving statins.3 Those latter investigators did not offer the hypothesis that prompted their study. However, we speculate that the evidence suggesting long-term preservation of cognitive function and the reduced presence of the pathologic changes associated with Alzheimer disease among elderly statin users might have prompted them to anticipate the opposite result.4–6 
There are numerous derivative questions. First, if the observations in both the retrospective studies mentioned above are valid, why the difference? Is it possible that the antiinflammatory effects of statins have a benefit that is evident in the context of the more intense proinflammatory state created by cardiopulmonary bypass? Is it simultaneously possible that there might also be adverse effects on cognitive function in other situations? Several considerations led us to suspect that there are grounds to suspect that statins might have adverse effects on cognitive function. Among the manifestations of the antiinflammatory effects of statins are reduced levels of nuclear factor-κB and tumor necrosis factor. However, nuclear factor-κB and tumor necrosis factor, in addition to their participation in systemic inflammatory process, are both present in the central nervous system in which they are important participants in synaptic function.7–10 
Furthermore, cholesterol itself is an important component of cell membranes and, in particular, is an essential element of membrane/lipid rafts (MLRs) that are essential for synaptic function.11 Our own recent investigations (manuscript in preparation) have revealed that genetic manipulations that increase MLR formation in neurons enhance synaptic signaling cascades and that this effect is blocked by statins or other agents that disrupt MLRs. Evidence obtained by others has shown that disruption or alterations of neuronal MLRs by statins can be neurotoxic, demonstrating the importance of these distinct microdomains for proper neuronal signaling.11–14 Other recent work has shown that the fatty acid content of MLRs isolated from synaptic endings is altered in aged animals.15 This, in turn, suggests that cognitive processes in the elderly might be more vulnerable to statin-associated changes in neuronal structure and function, of which delirium might be a manifestation.
The inherent paradox is that statins might be beneficial in terms of long-term cognitive well-being4–6 but yet be disadvantageous in the face of certain acute stresses, including anesthesia and surgery.3 This is currently at best a matter of reasonable speculation that requires further investigation. In the interim, our brief message is that we hope that clinicians and clinical investigators will keep their minds open to the possibility that statins might in some circumstances contribute to perioperative delirium or cognitive dysfunction.
*Veterans Administration Medical Center San Diego, San Diego, California.
Mantz J, Hemmings HC Jr, Boddaert J: Case scenario: Postoperative delirium in elderly surgical patients. Anesthesiology 2010; 112:189–95Mantz, J Hemmings, HC Boddaert, J
Katznelson R, Djaiani GN, Borger MA, Friedman Z, Abbey SE, Fedorko L, Karski J, Mitsakakis N, Carroll J, Beattie WS: Preoperative use of statins is associated with reduced early delirium rates after cardiac surgery. Anesthesiology 2009; 110:67–73Katznelson, R Djaiani, GN Borger, MA Friedman, Z Abbey, SE Fedorko, L Karski, J Mitsakakis, N Carroll, J Beattie, WS
Redelmeier DA, Thiruchelvam D, Daneman N: Delirium after elective surgery among elderly patients taking statins. CMAJ 2008; 179:645–52Redelmeier, DA Thiruchelvam, D Daneman, N
Etminan M, Gill S, Samii A: The role of lipid-lowering drugs in cognitive function: A meta-analysis of observational studies. Pharmacotherapy 2003; 23:726–30Etminan, M Gill, S Samii, A
Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JC, Montine TJ: Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007; 69:878–85Li, G Larson, EB Sonnen, JA Shofer, JB Petrie, EC Schantz, A Peskind, ER Raskind, MA Breitner, JC Montine, TJ
Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD: Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008; 71:344–50Cramer, C Haan, MN Galea, S Langa, KM Kalbfleisch, JD
Barger SW, Moerman AM, Mao X: Molecular mechanisms of cytokine-induced neuroprotection: NFκB and neuroplasticity. Curr Pharm Des 2005; 11:985–98Barger, SW Moerman, AM Mao, X
Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M, Beattie MS, Malenka RC: Control of synaptic strength by glial TNFα. Science 2002; 295:2282–5Beattie, EC Stellwagen, D Morishita, W Bresnahan, JC Ha, BK Von Zastrow, M Beattie, MS Malenka, RC
Pickering M, Cumiskey D, O'Connor JJ: Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 2005; 90:663–70Pickering, M Cumiskey, D O'Connor, JJ
McAfoose J, Koerner H, Baune BT: The effects of TNF deficiency on age-related cognitive performance. Psychoneuroendocrinology 2009; 34:615–9McAfoose, J Koerner, H Baune, BT
Hering H, Lin CC, Sheng M: Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci 2003; 23:3262–71Hering, H Lin, CC Sheng, M
Kumar B, Andreatta C, Koustas WT, Cole WC, Edwards-Prasad J, Prasad KN: Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. J Neurosci Res 2002; 68:627–35Kumar, B Andreatta, C Koustas, WT Cole, WC Edwards-Prasad, J Prasad, KN
Cerezo-Guisado MI, Garcia-Roman N, Garcia-Marin LJ, Alvarez-Barrientos A, Bragado MJ, Lorenzo MJ: Lovastatin inhibits the extracellular-signal-regulated kinase pathway in immortalized rat brain neuroblasts. Biochem J 2007; 401:175–83Cerezo-Guisado, MI Garcia-Roman, N Garcia-Marin, LJ Alvarez-Barrientos, A Bragado, MJ Lorenzo, MJ
Kannan M, Steinert JR, Forsythe ID, Smith AG, Chernova T: Mevastatin accelerates loss of synaptic proteins and neurite degeneration in aging cortical neurons in a heme-independent manner. Neurobiol Aging 2008 October 23. [Epub ahead of print]
Mateos MV, Salvador GA, Giusto NM: Selective localization of phosphatidylcholine-derived signaling in detergent-resistant membranes from synaptic endings. Biochim Biophys Acta 2009; 179:624–36Mateos, MV Salvador, GA Giusto, NM